Thursday, August 22 12:30–1:45pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 1)
Thursday, August 22 2–4:15pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 2)
Thursday, August 22 10–11am
Alzheimer Disease in Primary Care: Early Identification and New Anti-Amyloid Treatment Options
Thursday, August 22 10–11am
Alzheimer Disease in Primary Care: Early Identification and New Anti-Amyloid Treatment Options
Thursday, August 22 12:30–1:45pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 1)
Thursday, August 22 2–4:15pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 2)
Thursday, August 22 12:30–1:45pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 1)
Thursday, August 22 2–4:15pm
P.A.C.T.: Practical Approaches to Comprehensive Treatment of Pain (Part 2)
Thursday, August 22 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Thursday, August 22 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Disclosures
The following financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute. Relevant relationships will be disclosed at the start of each presentation.
Financial Disclosures
- Charles E. Argoff, MD, FABPM
- AbbVie, Amgen, Averitas Pharma, Biohaven, Grunenthal, Impel Pharmaceuticals, Kowa Pharmaceuticals America, Lilly, Lundbeck, Nevro, and Teva., Speaker; AbbVie, Amgen, Averitas Pharma, Clexio Biosciences, EnZen Therapeutics, Kowa, Lundbeck, Nevro, Tremeau Pharmaceuticals, Tris Pharma, Vertex and Xgene Pharma., Advisor; AbbVie, Amgen, Lilly, Lundbeck, and Teva., Researcher; Neumentum, PainScript, and Tris Pharma, Consultant; Pfizer and Trevena., Stock Holder (publicly traded company)
- Amy Clouse, MD, FAAFP
- Astellas Pharma, Advisor; Astellas Pharma, Speaker
- Anelyssa D'Abreu, MD, MPH, PhD
- No relevant financial relationships disclosed.
- Oscar A. de Leon-Casasola, MD
- Kowa Pharmaceuticals, Advisor; Kowa Pharmaceuticals, Consultant
- Katherine E. Galluzzi, DO, CMD, FACOFP
- No relevant financial relationships disclosed.
- Joynita R. Nicholson, DO, DABOM, FOMA
- Information to come
- Charles Vega, MD, FAAFP
- GlaxoSmithKline and Boehringer Ingelheim, Consultant
Other Disclosures
Pamela Kushner, MD, FAAFP (Moderator, Reviewer): Speaker for Astellas, Bayer, and Corcept; Speaker & Advisor for AstraZeneca, GlaxoSmithKline, Janssen, Novo Nordisk, Lilly/BI, and Phathom; Speaker & Consultant for Haleon; Advisor for Abbott, Bausch/SALIX, Intuity, and Pfizer; Consultant for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, and Lilly.
Charles Vega, MD (Moderator): Consultant for GlaxoSmithKline and Boehringer Ingelheim.
All other non-faculty contributors involved in the moderating, planning, development, editing and review of the content have disclosed no relevant financial relationships.